EU filing delay another blow to Takeda's alogliptin - updated
This article was originally published in Scrip
Executive Summary
Takeda is delaying for at least two and a half years the European filing of its oral antidiabetic alogliptin, while it conducts an additional long-term clinical study with the DPP-4 inhibitor.